Abstract
Mutations in the Nucleophosmin (NPM1) gene have been recently described to occur in about one-third of acute myeloid leukemias (AML) and represent the most frequent genetic alteration currently known in this subset. These mutations generate an elongated NPM1 protein that localizes aberrantly in the cytoplasm. In analogy with Flt3 alterations, NPM1 mutations are mostly detectable in AML with normal karyotype and their recognition may be relevant to identify distinct response to treatment. Hence, in addition to conventional karyotyping and RT-PCR of fusion genes, combined analysis of both Flt3 and NPM1 mutations will be increasingly relevant in the genetic diagnosis work-up of AML. We developed a multiplex RT-PCR assay followed by capillary electrophoresis to simultaneously analyze NPM1 and Flt3 gene alterations (NFmPCR assay). The assay was validated in leukemic cell RNAs extracted from 38 AML patients, which had been previously characterized for Flt3 status by conventional RT-PCR. Direct sequencing of NPM1 RT-PCR products was carried out in 15 cases to verify results obtained by capillary electrophoresis. Both NPM1 sequencing and conventional RT-PCR Flt3 results showed 100% concordance with the results of the NFmPCR assay. We suggest that this assay may be introduced in routine analysis of genetic alterations in AML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for the rapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 15: 4642–4649.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al, GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin (NPM) identifies a subtype of acute myelogenous leukemia with a normal karyotype and NPM1 gene mutations. N Engl J Med 2005; 352: 254–266.
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335.
Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.
Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190–195.
Rombouts WJ, Lowenberg B, van Putten WL, Ploemacher RE . Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. Leukemia 2001; 15: 1046–1053.
Martinelli G, Piccaluga PP, LoCoco F . FLT3 inhibition as tailored therapy for acute myeloid leukemia. Haematologica 2003; 88: 4–8.
Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185–2189.
Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H . Tryptophans 286 and 288 in the C-terminal region of protein B231 are important for its nucleolar localization. Biosci. Biotechnol Biochem 2002; 66: 2239–2242.
Chomczynsky P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate – phenol chloroform extraction. Anal Biochem 1987; 162: 156–159.
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928.
Liu QR, Chan PK . Characterization of seven processed pseudogenes of nucleophosmin/B23 in the human genome. DNA Cell Biol 1993; 12: 149–156.
Acknowledgements
This work was supported by MIUR Cofin 2003, and AIRC. At the time of the study, NIN was on leave of absence from the Department of Chemical Biochemistry (Hematology) Universidad Nacional de Rosario (Argentina) and EA was on leave of absence from the Division of Hematology of the University of Palermo (Italy). NIN is a member of Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET), Argentina.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Noguera, N., Ammatuna, E., Zangrilli, D. et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 19, 1479–1482 (2005). https://doi.org/10.1038/sj.leu.2403846
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403846
Keywords
This article is cited by
-
Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?
Journal of Hematopathology (2021)
-
Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia
Scientific Reports (2020)
-
Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing
Molecular Diagnosis & Therapy (2019)
-
NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome
Journal of Translational Medicine (2018)
-
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network
Annals of Hematology (2018)